MARKER FOR ASSESSING SENSITIVITY TO COMBINATION ANTICANCER DRUG
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Mar 17, 2022
app pub date -
Sep 26, 2019
filing date -
Sep 26, 2019
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A marker may determine sensitivity to an anti-cancer agent early after the start of treatment with the anti-cancer agent. The anti-cancer agent may include oxaliplatin or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker including one or more molecules selected from the group consisting of 2AMAD, 2ABA, 2CYPR, 5OPRO, 6AHXA, ADEN, ASP, BETNC, CARB, CSSG, DOPM, GGLCY, GSSG, HYPT, METSF, N6MDA, NOMTR, PHEP, PRO, and RIB5P.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully